Please enable Javascript
Video Insights
Roundtable: Focus on Leukemia
Roundtable: Focus on Myelodysplastic Syndromes
Advertisement
Advertisement
What Major Themes Define Recent Lower-Risk MDS Prognostication, Treatment?
Jamile Shammo, MD
Myelodysplastic Syndromes
|
October 21, 2024
Jamile Shammo, MD, leads a roundtable discussion on the effect of molecular data incorporation and goals in treatment.
View More
Dr. Swoboda on the Importance of MDS World Awareness Day
David Swoboda, MD
Myelodysplastic Syndromes
|
October 21, 2024
Dr. David Swoboda discusses the importance of MDS World Awareness Day and what makes MDS unique compared to other diseases.
View More
What to Know About Optimal Luspatercept Use in Lower-Risk MDS
Jamile Shammo, MD
Myelodysplastic Syndromes
|
October 21, 2024
The expert panel led by Jamile Shammo, MD, tells how trial data and their clinical experiences inform their use of the agent.
View More
What Is the Current MDS Treatment Landscape?
Guillermo Garcia-Manero, MD
Myelodysplastic Syndromes
|
October 16, 2024
A roundtable discussion, moderated by Guillermo Garcia-Manero, MD, discussed the current state of MDS treatment.
View More
Potential Benefits of Selinexor for CAR-T Therapies
Adriana Rossi, MD
Myeloma
|
October 16, 2024
Drs. Rossi and Khouri discuss two presentations on the effects of selinexor exposure on CAR-T outcomes in multiple myeloma.
View More
New Prognostic Model Predicts CNS Relapse in Patients With T-Cell Lymphomas
Melissa Badamo
T-Cell Lymphoma
|
October 9, 2024
Stefan K. Barta, MD, MS, discusses his recent study on central nervous system relapse in T-cell lymphomas.
View More
Dr. Abid on Sequencing Pirtobrutinib After CAR-T
Melissa Badamo
Transplantation & Cellular Therapy
|
October 4, 2024
Bilal Abid, MD, describes how to approach sequencing pirtobrutinib after CAR-T therapy.
View More
Dr. Luminari Remarks on EU Approval of Odronextamab for DLBCL, Follicular Lymphoma
Stefano Luminari, MD
Aggressive B-Cell Lymphoma
|
October 3, 2024
The positive safety profile of this bispecific antibody makes it well-suited for combination with other treatments.
View More
Dr. Kittai on Sequencing Pirtobrutinib With CAR-T for CLL
Adam Kittai, MD
Chronic Lymphocytic Leukemia
|
October 8, 2024
Adam Kittai, MD, discusses sequencing pirtobrutinib and CAR-T in the management of CLL with Richter transformation.
View More
Bilal Abid, MD, Discusses Bispecifics Versus CAR-T in the Community Setting
Melissa Badamo
Transplantation & Cellular Therapy
|
October 1, 2024
Dr. Abid describes when he uses bispecifics versus CAR-T in his practice at the University of Texas Health Science Center.
View More
Dr. Foss on Tipifarnib in Relapsed, Refractory, T-Cell Lymphoma
Melissa Badamo
T-Cell Lymphoma
|
September 27, 2024
The farnesyltransferase inhibitor tipifarnib achieved an ORR of 40% and a median duration of response of 3.7 months.
View More
Salvia Jain Lab Integrates Machine Learning to Predict T-Cell Lymphoma Outcomes
Melissa Badamo
T-Cell Lymphoma
|
September 27, 2024
The PETAL Consortium at the Jain Lab integrates AI-informed digital interface as a tool to facilitate clinical decisions.
View More
Guillermo Garcia-Manero, MD, Shares Recent Progress in Low-Risk MDS
Melissa Badamo
Myelodysplastic Syndromes
|
September 26, 2024
Dr. Garcia-Manero discussed luspatercept, a first-in-class drug for patients with low-risk MDS and anemia.
View More
Dr. Coombs on Second Generation BTK Inhibitors for CLL
Catherine Coombs, MD
Chronic Lymphocytic Leukemia
|
September 25, 2024
The newer agents have distinguished themselves especially by having safety profiles superior to ibrutinib.
View More
Dr. Rogers Discusses Takeaways From the CLL Debate at SOHO 2024
Melissa Badamo
Chronic Lymphocytic Leukemia
|
September 25, 2024
Dr. Rogers debated against Inhye Ahn, MD, on whether therapy with Bruton tyrosine kinase inhibitors can be discontinued.
View More
Dr. Coombs on Exciting CLL Therapies at SOHO 2024
Catherine Coombs, MD
Chronic Lymphocytic Leukemia
|
September 25, 2024
Dr. Coombs discussed time limited therapies and the phase III AMPLIFY trial of acalabrutinib plus venetoclax in CLL.
View More
Dr. Chedid on Phase III COMMANDS Findings in MDS, Anemia
Solly Chedid, MD
Myelodysplastic Syndromes
|
September 30, 2024
COMMANDS is the first trial to perform a head-to-head comparison of luspatercept against an erythropoiesis-stimulating agent.
View More
Dr. Bose on JAK Inhibitor Optimization, Trial Updates in Myelofibrosis
Prithviraj Bose, MD
Myelofibrosis
|
September 25, 2024
An expert on myelofibrosis comments on promising results from current trials and on the need for useful clinical biomarkers.
View More
Dr. Yasenchak on ECHELON-3 Combination Therapy Results in DLBCL
Christopher Yasenchak, MD
Aggressive B-Cell Lymphoma
|
September 25, 2024
Brentuximab vedotin plus lenalidomide and rituximab combination showed promising efficacy and potential as bridging therapy.
View More
Dr. Jennifer Brown Highlights Recent Advances in CLL Care at SOHO 2024
Jennifer R. Brown, MD, PhD
Chronic Lymphocytic Leukemia
|
October 9, 2024
The past year in CLL care has seen promising new study findings on BTK inhibition and regulatory approvals.
View More
Dr. Jabbour Discusses Obe-cel in ALL
Elias Jabbour, MD
Acute Lymphoblastic Leukemia
|
September 10, 2024
In the FELIX trial, obe-cel, a CAR-T therapy, achieved a 78% response rate and a 97% MRD negativity rate.
View More
Dr. Shaughnessy Outlines FELIX Trial of Obe-Cel in Relapsed, Refractory B-ALL
Patrick Daly
Acute Lymphoblastic Leukemia
|
September 16, 2024
Of the 127 patients who received obe-cel infusion, 74% achieved CR/CRi and 95% had MRD negativity.
View More
KLRG1 Cell Depletion Offers Novel Therapeutic Strategy for T-Cell Lymphoma
Melissa Badamo
T-Cell Lymphoma
|
August 19, 2024
Treatment with the monoclonal antibody 208 alone, and in combination with duvelisib, extended survival.
View More
Dr. Raddi on Predictors of Response to ESA in MDS
Marco Gabriele Raddi, MD
Myelodysplastic Syndromes
|
August 19, 2024
Dr. Raddi discusses his study on identifying predictors of response to ESA therapy in patients with lower-risk MDS.
View More
How Will AML Treatment Evolve?
Eric Winer, MD
Video Insights
|
July 30, 2024
Drs. Winer, Daver, and Abaza discuss how the treatment of AML will evolve in the future.
View More
Study Highlights Importance of Immunoglobulin G Screening in Patients With CLL, NHL
Melissa Badamo
Chronic Lymphocytic Leukemia
|
August 14, 2024
Patients who received at least three IgG tests were less likely to have severe infections compared with those who didn't.
View More
Thomas Martin, MD, Looks Forward to SOHO 2024
Melissa Badamo
Video Insights
|
July 24, 2024
The SOHO 2024 Annual Meeting will take place September 4-7, 2024, in Houston, Texas.
View More
Lore Gruenbaum, PhD, Discusses the LLS Therapy Acceleration Program
Melissa Badamo
Video Insights
|
July 22, 2024
The foundation conducts partnerships with companies to provide funding to accelerate novel blood cancer therapies.
View More
Prithviraj Bose, MD, Talks Novel Myelofibrosis Therapies
Melissa Badamo
Myelofibrosis
|
July 24, 2024
New therapies, such as TP-3654, are currently being explored in combination studies.
View More
Dr. Martin Highlights Recent Myeloma Research at EHA 2024
Melissa Badamo
Myeloma
|
July 24, 2024
Dr. Martin highlighted research in quadruplet therapy, CAR-T therapy, and bispecific T-cell engagers.
View More
View All Videos
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Subscribe Now
Knowledge Hubs
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Aggressive B-Cell Lymphoma
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Hodgkin Lymphoma
Indolent B-Cell Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
Myeloma
MDS
MPN
Myelofibrosis
Transplantation & Cellular Therapy
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Aggressive B-Cell Lymphoma
Chronic Lymphocytic Leukemia
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACP
Editor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MD
Executive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Thomas Martin, MD
Associate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MD
Associate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPH
Associate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Guillermo Garcia-Manero, MD
Associate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Kami Maddocks, MD
Associate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University